BGB324 (bemcentinib), a selective oral AXL inhibitor, has shown synergistic anti-tumor activity with immune checkpoint inhibitor by overcoming immune suppression conferred by STK11 mutation in a NSCLC xenograft mouse model (96). This evidence concerns the gene AXL and non-small cell lung carcinoma.